-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 8, the first in class hypoglycemic drug dorzagliatin developed by Hua Ling Pharmaceutical was officially approved for marketing
Dopaglietin is a world-first glucokinase initiator (GKA) designed to control the progressive degenerative properties
Doglidine molecular structure
A phase III clinical study code-named SEED evaluated the efficacy
The results showed that at week 24, the saccharified hemoglobin (HbA1c) in the treatment group decreased by 1.
Another key phase III study (DAWN) evaluated the efficacy
The results showed that at week 24, HbA1c was reduced by 1.
In August 2020, Hualing Pharmaceutical and Bayer reached a cooperation to be responsible for clinical development, registration, product supply and distribution as the holder of the drug marketing license
Hua Ling Pharmaceutical will receive an advance payment of RMB300 million, in addition to an additional milestone payment